ACADIA Pharmaceuticals Inc (MEX:ACAD)
MXN 509 0 (0%) Market Cap: 50.07 Bil Enterprise Value: 41.15 Bil PE Ratio: 83.33 PB Ratio: 4.82 GF Score: 75/100

ACADIA Pharmaceuticals Inc Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin - Corporate Call Transcript

Nov 25, 2019 / 10:00PM GMT
Operator

Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals conference call to discuss the ADVANCE study results. My name is Catherine, and I'll be your coordinator for today. (Operator Instructions)

I would now like to turn the presentation over to Mr. Mark Johnson, Vice President of Investor Relations at ACADIA. Please proceed.

Mark C. Johnson
ACADIA Pharmaceuticals Inc. - VP of IR

Thank you, Catherine. Good afternoon, and thank you for joining us on today's call to discuss the positive top line results from the ADVANCE study evaluating pimavanserin as a treatment for the negative symptoms of schizophrenia.

On today's call, Steve Davis, our Chief Executive Officer, will provide opening remarks. Following Steve, Dr. Serge Stankovic, our President, will discuss the ADVANCE results in greater detail. Following Steve's closing remarks, we will conduct a Q&A session. Michael Yang, our Chief Commercial Officer; and Elena Ridloff, our Chief Financial Officer, will be also available for Q&A.

I would also like to point

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot